Clinical trials
Solid Cancers clinical trials
Below are recruiting solid cancers clinical trials, each written for real people, not researchers. We’re tracking 920 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03514368Recruiting
Testing immune markers to track cancer treatment safety and benefit
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
ToulouseAges 18 years+ - NCT06050733Recruiting
Gut bacteria and immunotherapy response in solid tumors
This study looks at how the bacteria in your gut may affect how well immunotherapy works for solid cancers that have spread or cannot be removed. It focuses on people who have been on certain immunotherapy drugs (PD-1 or PD-L1 inhibitors) for at least 3 months but less than 2 years.
Galveston, TexasAges 35–75 - NCT07484932Recruiting
Tailored Treatment Dosing for Older Adults with Cancer
This trial tests a new dosing strategy (called TRTRM or ACTTOP) to find the right amount of cancer treatment for patients aged 65 and older. It aims to reduce side effects while keeping the treatment effective.
Hong KongAges 65 years+ - NCT06006390RecruitingPhase 1/Phase 2
CAR-T therapy for CEA-positive advanced solid tumors
This trial tests a new treatment called CAR-T cells that are designed to find and attack cancer cells carrying a protein called CEA. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried other treatments.
Taiyuan, ShanxiAges 18 years+ - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT05483374Recruiting
Head and neck cancer registry for adult patients
This study builds a European database (registry) of adults with certain head and neck cancers to better understand how these cancers are diagnosed and treated over time. It may help future care by collecting real-world information, rather than testing a new medicine.
Brno, BrnoAges 18 years+ - NCT05403554RecruitingPhase 1
Testing a new mesothelin-targeting drug for certain solid cancers
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
ParisAges 18 years+ - NCT05504772Recruiting
Personalized genetic testing for children with cancer
This trial studies how personalized (tailored) genetic testing can help guide care for children with cancer. It may help match treatment choices to each child’s genetic risk, and it includes optional return of germline (inherited) test results.
AdelaideAges birth–25 years - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07066657RecruitingPhase 1
Study of MRG007 for advanced solid tumors
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
Los Angeles, CaliforniaAges 18 years+ - NCT07179692RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a type of immunotherapy called CAR-T, which is designed to recognize and attack cancer cells that have a protein called CEA on their surface. It's for people with advanced cancers like colorectal, esophageal, gastric, pancreatic, lung, or bile duct cancer who have tried at least two standard treatments.
Hefei, AnhuiAges 18 years+ - NCT05187338RecruitingPhase 1/Phase 2
Study drugs that target immune checkpoints for solid tumors
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
Guangzhou, GuangdongAges 18–70 - NCT06253871RecruitingPhase 1
Study of IAM1363 for HER2 Cancers
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
La Jolla, CaliforniaAges 18 years+ - NCT04282031RecruitingPhase 1/Phase 2
BPI-1178 for advanced breast cancer or solid tumors
This early-phase study tests BPI-1178 in people with advanced (stage 4 or hard-to-treat) solid tumors, including HR+/HER2- breast cancer. It looks at how well the treatment works and how safe it is, especially after standard treatments have stopped working or aren’t an option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07358806RecruitingPhase 1
Study of OCT-598 for advanced solid tumors
This trial tests a new drug called OCT-598, alone or with chemotherapy, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
Goyang-siAges 18 years+ - NCT06010862RecruitingPhase 1
CAR-T therapy for CEA-positive advanced cancers
This trial tests a new type of immune cell therapy (called CAR-T) that targets a protein called CEA on cancer cells. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried standard treatments without success.
Nanchang, JiangxiAges 18 years+ - NCT05740956RecruitingPhase 1
Drug study for cancers with HRR gene or HRD changes
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
Beijing, Beijing MunicipalityAges 18–75 - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Tucson, ArizonaAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT05856981RecruitingPhase 1
Testing ADU-1805 for advanced solid tumors safety
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
Detroit, MichiganAges 18 years+ - NCT06439888RecruitingPhase 1/Phase 2
Immune cells plus radiation for limited-stage cancer spread
This trial tests whether giving immune-supporting cells (lymphocytes) alongside focused radiation (SBRT) can help control limited cancer spread. People with 1 to 5 small tumors that can all be radiated within two weeks may be eligible.
LyonAges 18 years+ - NCT06606990RecruitingPhase 1
Testing the drug CX-5461 for advanced solid tumors
This trial tests a new drug called CX-5461 (also known as pidnarulex) in people whose cancer has spread and hasn't been helped by standard treatments. It looks at how your body responds to the drug, which may target cancers with specific DNA repair problems.
Bethesda, MarylandAges 18 years+ - NCT06926075RecruitingPhase 1/Phase 2
Early trial of KESONOTIDE™ for solid tumors
This trial tests a new tablet called KESONOTIDE™ for people with solid tumors that have spread. The goal is to see if it can help when other treatments have stopped working or are not an option.
Kogarah, New South WalesAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Duarte, CaliforniaAges 18 years+
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid cancers?
- Yes. Clin2 currently lists 920 recruiting solid cancers studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid cancers trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid cancers trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.